RSLCX
Price
$79.44
Change
+$0.67 (+0.85%)
Updated
Jun 22 closing price
Net Assets
91.47B
TGSAX
Price
$10.57
Change
-$0.07 (-0.66%)
Updated
Jun 22 closing price
Net Assets
810.82M
Interact to see
Advertisement

RSLCX vs TGSAX

RSLCX vs TGSAX Comparison Chart in %
View a ticker or compare two or three
VS
RSLCX vs. TGSAX commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RSLCX is a Buy and TGSAX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RSLCX has more cash in the bank: 91.5B vs. TGSAX (811M). TGSAX pays higher dividends than RSLCX: TGSAX (1.42) vs RSLCX (0.46). RSLCX was incepted earlier than TGSAX: RSLCX (24 years) vs TGSAX (29 years). RSLCX (1.30) is less costly to investors than TGSAX (1.09). RSLCX is a more actively managed with annual turnover of: 41.00 vs. TGSAX (15.75). RSLCX has a lower initial minimum investment than TGSAX: RSLCX (250) vs TGSAX (100000). RSLCX annual gain was more profitable for investors over the last year : 23.11 vs. TGSAX (16.30). RSLCX return over 5 years is better than : -3.20 vs. TGSAX (-8.98).
RSLCXTGSAXRSLCX / TGSAX
Total Expense Ratio1.301.09119%
Annual Report Gross Expense Ratio1.301.09119%
Fund Existence24 years29 years-
Gain YTD16.68611.181149%
Front LoadN/AN/A-
Min. Initial Investment2501000000%
Min. Initial Investment IRAN/AN/A-
Net Assets91.5B811M11,282%
Annual Yield % from dividends0.461.4233%
Returns for 1 year23.1116.30142%
Returns for 3 years41.2227.81148%
Returns for 5 years-3.20-8.9836%
Returns for 10 years96.6741.07235%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ACFOX82.27N/A
N/A
American Century Focused Dynamic Gr Inv
UMBHX28.65N/A
N/A
Carillon Chartwell Small Cap I
AMTAX11.54N/A
N/A
AB All Market Real Return A
MDOBX12.01N/A
N/A
Morgan Stanley Developing Opportunity C
JVACX39.17N/A
N/A
JPMorgan Value Advantage C